Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 11, 2025 08:00 ET | Source: Chemomab Therapeutics

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

FDA agreement on CMC requirements and the timing of non-clinical toxicology testing are milestones further advancing nebokitug towards a PSC Phase 3 trial.
June 03, 2025 08:00 ET | Source: Chemomab Therapeutics

Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

New patents in China and Russia further strengthen nebokitug's extensive intellectual property portfolio in the US, Europe and other major territories.
April 21, 2025 08:00 ET | Source: Chemomab Therapeutics

Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

Clinical data on Chemomab's nebokitug for the treatment of PSC will be presented at the scientific conferences DDW25; EASL 2025 and BSG LIVE'25
April 15, 2025 08:00 ET | Source: Chemomab Therapeutics

Chemomab Announces New Medical and Clinical Appointments

David Weiner, MD, is rejoining Chemomab as Interim Chief Medical Officer and Clinical Development SVP Jack Lawler has been named Chief Development Officer.